Another stress inducer is the proteasome inhibitor Bortezomib (Btz), the first one approved by the Food and Drug Administration, for treating mantle cell lymphoma and multiple myeloma, and we demonstrated that used in combination with RA and ATO efficiently causes FLT3-ITD + AML cell death [30]. This evidence concerns the gene FLT3 and acute myeloid leukemia.